Advertisement

Advertisement

NCCN 2021 Virtual Congress: Hematologic Malignancies

Leukemia

Novel Therapies Under Study in Acute Myeloid Leukemia

Newly identified genetic abnormalities in acute myeloid leukemia (AML), as well as therapies that can target some of those abnormalities, are now available as the landscape for treatment continues to ...

Leukemia

Novel Therapies Under Study in Acute Myeloid Leukemia

Newly identified genetic abnormalities in acute myeloid leukemia (AML), as well as therapies that can target some of those abnormalities, are now available as the landscape for treatment continues to ...

Lymphoma
Immunotherapy

Newer Agents on the Horizon for Refractory or Relapsed DLBCL

Although treating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains challenging, some newer therapies on the horizon offer promise, including bispecific antibodies, an...

hematologic malignancies

Ronald S. Go, MD, on Managing Histiocytic Neoplasms: New NCCN Guidelines

Ronald S. Go, MD, of Mayo Clinic Cancer Center, discusses the new NCCN Clinical Practice Guidelines in Oncology for the most common types of histiocytic neoplasms in adults—Erdheim-Chester disease, La...

multiple myeloma

Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?

Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the evolving treatment paradigm for patients with newly diagnosed multiple myeloma in which clinical trials are suggesting the addition ...

Hematologic Malignancies

Numerous Regimens Proposed for Relapsed or Refractory Myeloma

Although patients with multiple myeloma can respond to initial treatment, once a patient has had three or four different types of therapy, and the disease is deemed relapsed or refractory, treatment b...

leukemia
lymphoma

Jennifer A. Woyach, MD, on CLL/SLL: Using Minimal Residual Disease Assessment in Clinical Practice

Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, talks about whether modifications of treatment based on minimal residual disease is beneficial to patients with chroni...

leukemia

Alice S. Mims, MD, on AML: Updates on Managing Newly Diagnosed Disease

Alice S. Mims, MD, of The Ohio State University Comprehensive Cancer Center, discusses the many positive changes over the past 5 years in treating patients with newly diagnosed acute myeloid leukemia ...

Advertisement

Advertisement



Advertisement